+

WO2001026679A3 - Cellules et molecules impliquees dans l'immunoregulation - Google Patents

Cellules et molecules impliquees dans l'immunoregulation Download PDF

Info

Publication number
WO2001026679A3
WO2001026679A3 PCT/CA2000/001172 CA0001172W WO0126679A3 WO 2001026679 A3 WO2001026679 A3 WO 2001026679A3 CA 0001172 W CA0001172 W CA 0001172W WO 0126679 A3 WO0126679 A3 WO 0126679A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
molecules involved
immune regulation
regulatory
osteopontin
Prior art date
Application number
PCT/CA2000/001172
Other languages
English (en)
Other versions
WO2001026679A2 (fr
Inventor
Li Zhang
Zhu Xu Zhang
Liming Yang
Original Assignee
Li Zhang
Zhu Xu Zhang
Liming Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Li Zhang, Zhu Xu Zhang, Liming Yang filed Critical Li Zhang
Priority to EP00965696A priority Critical patent/EP1223963A2/fr
Priority to AU76369/00A priority patent/AU7636900A/en
Publication of WO2001026679A2 publication Critical patent/WO2001026679A2/fr
Publication of WO2001026679A3 publication Critical patent/WO2001026679A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4277—Fusion proteins originating from gene translocation in cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des cellules et des molécules impliquées dans l'immunorégualtion. Ces cellules sont des lymphocytes T régulateurs dotés du phénotype CD3+αβTCR?+CD4-CD8-CD44-CD28-NK1.1-¿. Ces lymphocytes régulateurs expriment des niveaux élevés de Ly-6A et d'ostéopontine alors que des cellules non régulatrices ne le font pas. Une inhibition de Ly-6A ou d'ostéopontine inhibe les propriétés suppressives des cellules.
PCT/CA2000/001172 1999-10-08 2000-10-06 Cellules et molecules impliquees dans l'immunoregulation WO2001026679A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00965696A EP1223963A2 (fr) 1999-10-08 2000-10-06 Cellules et molecules impliquees dans l'immunoregulation
AU76369/00A AU7636900A (en) 1999-10-08 2000-10-06 Novel cells and molecules involved in immune regulation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15813299P 1999-10-08 1999-10-08
US60/158,132 1999-10-08
US22657300P 2000-08-21 2000-08-21
US60/226,573 2000-08-21

Publications (2)

Publication Number Publication Date
WO2001026679A2 WO2001026679A2 (fr) 2001-04-19
WO2001026679A3 true WO2001026679A3 (fr) 2001-10-25

Family

ID=26854767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001172 WO2001026679A2 (fr) 1999-10-08 2000-10-06 Cellules et molecules impliquees dans l'immunoregulation

Country Status (4)

Country Link
EP (1) EP1223963A2 (fr)
AU (1) AU7636900A (fr)
CA (1) CA2316089A1 (fr)
WO (1) WO2001026679A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468020A1 (fr) * 2001-11-21 2003-06-05 The Board Of Trustees Of The Leland Stanford Junior University Compositions et methodes associees a l'osteopontine
US20030147865A1 (en) * 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
AU2003285586A1 (en) * 2002-12-03 2004-06-23 Medical Research Council Regulatory t-cells
US20160158352A1 (en) * 2013-07-10 2016-06-09 The United States of America, as represented by the Secretary, Department of Health & Human Servic Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009234A2 (fr) * 1991-11-05 1993-05-13 The Board Of Trustees Of The Leland Stanford Junior University Cellules supresseurs et souches
JPH0733680A (ja) * 1993-07-16 1995-02-03 Kirin Brewery Co Ltd 免疫抑制剤
WO1998056405A1 (fr) * 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research Procede utilisant l'osteopontine pour moduler une reponse immunitaire

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009234A2 (fr) * 1991-11-05 1993-05-13 The Board Of Trustees Of The Leland Stanford Junior University Cellules supresseurs et souches
JPH0733680A (ja) * 1993-07-16 1995-02-03 Kirin Brewery Co Ltd 免疫抑制剤
WO1998056405A1 (fr) * 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research Procede utilisant l'osteopontine pour moduler une reponse immunitaire

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199515, Derwent World Patents Index; Class B04, AN 1995-110563, XP002166819 *
DUMONT F J: "DIVERGENT EFFECTS OF CYCLOSPORINE A ON INTERFERON AND MITOGEN-INDUCED LY-6A ANTIGEN SUGGEST AUTOCRINE REGULATION OF LY-6A EXPRESSION IN ACTIVATED T CELLS", CELLULAR IMMUNOLOGY, vol. 105, no. 2, 1987, pages 355 - 365, XP000992908, ISSN: 0008-8749 *
LANIER L L ET AL: "HUMAN CD-3-POSITIVE T LYMPHOCYTES THAT EXPRESS NEITHER CD-4 NOR CD-8 ANTIGENS", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 164, no. 1, 1986, pages 339 - 344, XP000992909, ISSN: 0022-1007 *
STANFORD WILLIAM L ET AL: "Altered proliferative responses by T lymphocytes of Ly-6A (Sca-1) null mice.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 5, 1997, pages 705 - 717, XP000992931, ISSN: 0022-1007 *
WEBER G F ET AL: "THEIMMUNOLOGY OF ETA-1/OSTEOPONTIN", CYTOKINE AND GROWTH FACTOR REVIEWS,OXFORD,GB, vol. 7, no. 3, October 1996 (1996-10-01), pages 241 - 248, XP000982501, ISSN: 1359-6101 *
ZHANG ZHU-XU ET AL: "Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression.", NATURE MEDICINE, vol. 6, no. 7, July 2000 (2000-07-01), pages 782 - 789, XP002166818, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
WO2001026679A2 (fr) 2001-04-19
CA2316089A1 (fr) 2001-04-08
EP1223963A2 (fr) 2002-07-24
AU7636900A (en) 2001-04-23

Similar Documents

Publication Publication Date Title
IL131332A (en) Methods and products for analyzing polymers
DE69840025D1 (de) Assoziierter antworten
LU91758I9 (fr)
IT1286361B1 (it) Supporto integrato di isolamento sismico nella direzione orizzontale e verticale
EG21900A (en) Polyfin composition with molecular weight maximum occurring inthat part of the composition that has the highest comonomer content
BR9710462A (pt) Naftopirans composicoes e artigos contendo as mesmas
AU134374S (en) Container for wipes or the like
EP0616199A3 (fr) Boîte dynamométrique et dispositif de pesage l'utilisant.
PT777611E (pt) Contentor com uma area transparente
DE58906377D1 (en) Difluormethylverbindungen.
NZ508110A (en) Attenuated mutants of salmonella which constitutively express the Vi antigen
EP2196472A3 (fr) Compositions et procédés permettant de générer une réponse immunitaire au moyen de systèmes de vecteurs à base d'alphavirus
ZA963997B (en) Lubricants with molybdenum containing compositions and methods of using the same.
EP1026182A4 (fr) Quatre composants copolymeres et lentilles oculaires fabriquees a l'aide de ces composants
AU1392095A (en) Maleimide copolymer and resin composition containing the same
EP1582556A4 (fr) Film de polyester thermoretractable
EP0748862A3 (fr) Des compositions lubrifiantes, des fluides fonctionnels et des graisses contenant des esters thiophosphoriques avec un groupe oxyalkylène ou leurs sels, et leurs procédés d'utilisation
GR3029483T3 (en) Antibodies against t-cells as therapeutics
WO2001026679A3 (fr) Cellules et molecules impliquees dans l'immunoregulation
UA48245C2 (uk) ЗАМІЩЕНІ 1,2,3,4-ТЕТРАГІДРО-2-ДИБЕНЗОФУРАНАМІНИ ТА 2-АМІНОЦИКЛОГЕПТА[B]БЕНЗОФУРАНИ, ФАРМАЦЕВТИЧНА ЛІКАРСЬКА ФОРМА ТА СПОСІБ ПІДВИЩЕННЯ АКТИВАЦІЇ 5-НТ<sub>1F</sub> РЕЦЕПТОРА У ССАВЦЯ
BG100248A (en) Squalene synthetase inhibitors
DK0925283T3 (da) Hidtil ukendte polymeriserbare acylimidazolidinonmonomerer
AU6496094A (en) Tumor-associated antigens recognized by t cells and the uses of these antigens
ZA945708B (en) Rye-flour
GR3034675T3 (en) Polymer composition, the production and further processing thereof into receptacles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000965696

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000965696

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000965696

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载